Literature DB >> 3488121

Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin 1.

E V Gaffney, S C Tsai.   

Abstract

Several native and recombinant forms of human interleukin-1 (IL-1) and recombinant murine IL-1 were assayed for their ability to inhibit the growth of cell lines established from malignant and nonmalignant human sources. The amount of growth-inhibitory activity was compared to the units of half-maximal [3H]thymidine incorporation in mouse thymocyte cultures exposed to IL-1. Three malignant human mammary cell lines (MCF-7, T47D, and MDA-MB-415) were growth inhibited in the presence of both native and the alpha and beta forms of recombinant human IL-1. MDA-MB-415 was most sensitive. Although most sources of IL-1 showed good correlation between units of activity and percentage of growth inhibition, native IL-1 from Genzyme Corporation induced a cytotoxic effect. Murine IL-1 was less growth inhibitory than the human forms of the monokine. Human embryonic lung (HEL), adult fibroblast (CRL 1445), and transformed milk (HBL-100) lines were not growth inhibited when tested against any IL-1 source. A lung carcinoma (CALU-1) and a colon carcinoma (SW-48) were not inhibited by either the alpha or beta forms of human recombinant IL-1.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488121

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Existence of both IL-1 alpha and beta in normal human amniotic fluid: unique high molecular weight form of IL-1 beta.

Authors:  T Tamatani; H Tsunoda; H Iwasaki; M Kaneko; T Hashimoto; K Onozaki
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

2.  Production of tumor necrosis factors by human T cell lines infected with HTLV-1 may cause their high susceptibility to human immunodeficiency virus infection.

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

3.  Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on growth factor expression in the human breast cancer cell line MCF-7.

Authors:  C Vogel; J Abel
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

4.  Recombinant interleukin-1 alpha inhibits the growth of rat mesangial cells in culture.

Authors:  M Ikeda; U Ikeda; T Oohara; K Takeda; S Kano
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

5.  Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity.

Authors:  R J North; R H Neubauer; J J Huang; R C Newton; S E Loveless
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

6.  The zinc finger transcription factor EGR-1 impedes interleukin-1-inducible tumor growth arrest.

Authors:  S F Sells; S Muthukumar; V P Sukhatme; S A Crist; V M Rangnekar
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

7.  Purification of platelet-derived endothelial cell growth inhibitor and its characterization as transforming growth factor-beta type 1.

Authors:  S Magyar-Lehmann; P Böhlen
Journal:  Experientia       Date:  1992-04-15

8.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

9.  Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer.

Authors:  L Kaklamanis; K C Gatter; N Mortensen; A L Harris
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

10.  Interleukin-1 production by immunologically hyporeactive tumour-bearing mice.

Authors:  V Holán; M Lipoldová
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.